Bolt Biotherapeutics, Inc. Restructuring Charges
Bolt Biotherapeutics, Inc. (BOLT) reported Restructuring Charges of $1.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. restructuring charges for the quarter ending 2025-12-31 was $1.48M.
- Bolt Biotherapeutics, Inc. restructuring charges for the quarter ending 2025-09-30 was $0.00.
- Bolt Biotherapeutics, Inc. restructuring charges for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Bolt Biotherapeutics, Inc. restructuring charges for the quarter ending 2025-03-31 was $0.00.
- Bolt Biotherapeutics, Inc. restructuring charges for fiscal 2025 was $1.48M, a 55.73% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. restructuring charges for fiscal 2024 was $3.34M.
- Bolt Biotherapeutics, Inc. restructuring charges for fiscal 2023 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.48M derived: sum of 2 quarters · filed 2026-03-12 | $1.48M derived: sum of 3 quarters · filed 2026-03-12 | $1.48M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | -$222.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | -$222.00K derived: sum of 3 quarters · filed 2026-03-12 | -$222.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-12 | -$222.00K derived: sum of 2 quarters · filed 2026-03-12 | -$222.00K derived: sum of 3 quarters · filed 2026-03-12 | $3.34M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | -$222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$222.00K derived: sum of 2 quarters · filed 2026-03-12 | $3.34M derived: sum of 3 quarters · filed 2026-03-12 | $3.34M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $3.56M derived: sum of 2 quarters · filed 2025-11-12 | $3.56M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $3.56M 10-Q · filed 2025-08-14 | $3.56M 10-Q · filed 2025-08-14 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |